NCT02539225

A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 191 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the effectiveness of S-1 and oxaliplatin with or without ramucirumab as first line therapy in participants with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Conditions

• Metastatic Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Ramucirumab	Administered IV
DRUG	Placebo	Administered IV
DRUG	S-1	Administered PO
DRUG	Oxaliplatin	Administered IV
DRUG	Paclitaxel	Administered IV

Timeline

• Start date: 2015-10-05
• Primary completion: 2017-10-25
• Completion: 2021-03-10
• First posted: 2015-09-02
• Last updated: 2022-03-08
• Results posted: 2019-02-15

Locations

34 sites across 3 countries: Japan, South Korea, Taiwan